[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642928":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":10,"responsibleParty":27,"collaborators":10,"id":29,"slug":10,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":46,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":10},{"fullName":5,"class":6},"Gruppo Italiano Malattie EMatologiche dell'Adulto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with chronic myeloid leukemia treated with asciminib in the real-life",null,"Patients with chronic phase myeloid leukemia treated in second or subsequent lines with asciminib according to clinical practice",[13],{"name":14,"affiliation":15,"role":16},"Massimo Breccia","Sapienza University, Rome","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Paola Fazi","CONTACT","+39 0670390528","p.fazi@gimema.it",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},"Enrico Crea","+390670390514","e.crea@gimema.it",{"type":28,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100642928",false,"NCT07640750","Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines","Retrospective and Prospective Observational Study on the Efficacy and Tolerability of Asciminib in Real-world Clinical Practice in Patients With Chronic Myeloid Leukemia Treated in Second or Subsequent Lines: ASCIRLI (ASCIminib in Real-Life Italy)","ASCIRLI","Inclusion Criteria:\n\n1. Patients aged ≥ 18 years and no upper age limit;\n2. Patients with a diagnosis of CML-CP who started treatment with asciminib according to clinical practice - from the date of commercial availability of asciminib - until the end of recruitment period (two years after the first patient included);\n3. Patients treated with asciminib in second or subsequent lines of therapy (≥2L)\n4. Patients who provide written informed consent to participate in the study (if applicable).\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":39,"type":40},98,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the efficacy and tolerability of asciminib in real-life in patients with chronic myeloid leukemia treated in second or subsequent lines. The main object of the study is to assess the achievement of Major Molecular Response.",[44,45],"Chronic Myeloid Leukemia","Chronic Myeloid Leukemia - Chronic Phase",[47,48,49,50],"chronic myeloid leukemia","asciminib","real-life","second line","NOT_YET_RECRUITING","2026-06-08",{"date":54,"type":55},"2026-06-11","ACTUAL",{"date":57,"type":40},"2026-09-01",{"date":59,"type":40},"2031-12-01",{"name":5,"class":6}]